IMPT
Four patients (7.8%) treated with IMPT required NG-tube placement, compared 12 patients (15%) treated with VMAT (p-value = 0.026) ( Table 2 ). The mean percentage body weight lost during radiotherapy was 4.87% in the IMPT group and 6.21% in the VMAT group (p-value =0.038). Sixteen patients (20%) treated with IMPT had body weight lost over 7 %, compared with 28 patients (35%) treated with VMAT (p-value = 0.034). Gade 3 dermatitis with wound care is the most common adverse event, and there were great difference between IMPT group 28 patients (35%) and VMAT group 6 patients (7.5%) (p<0.000) ( Table 2 ). There were no differences in acute grade 3 mucositis and grade 2-3 xerostomia between the IMPT and VMAT patients. No differences were found between the two groups in the frequency of emergency room visits or in unscheduled hospitalizations.
Chemotherapy compliance and hematologic adverse event
sixteen-nine patients in IMPT group and seventeen patients in VMAT group were received concurrent chemotherapy. Seven (10.1%) patients in IMPT group could not complete schedule chemotherapy with total dose of 200 mg/m2 of cisplatin, compared with 12 (17.4%) patients in VMAT group (P= 0.230). The frequency and grade of neutropenia were significantly different between patient treated with IMPT and VMAT. In IMPT group, 15.9% patients experience grade 1 neutropenia and 7.2% patients experienced ≥ Gr 2 neutropenia, compared with 28.6% and 14.3% patients experienced Gr 1 neutropenia and ≥ Gr 2 neutropenia respectively in VMAT group (P= 0.048) (Table 3) Table 1 . No imbalances were found between the two groups. Median follow-up time were respectively 13 months (range: 6 -29) and 36 months (range 6-56) for IMPT and VMAT patients. 2-years PFS rate of 96.2% in the IMPT group and 83.7% in the VMAT group (Figure 1) . CONCLUSION   TABLE 1   TABLE 2  TABLE 3 FIGURE 1
IMPT is associated with reduced rates of NG-tube insertion, weight loss during radiotherapy and hematologic adverse events. The oncologic outcome may potentially improved by reduction toxicity for nasopharyngeal cancer patients treated with IMPT.
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